A low-dose combination therapy of interleukin-2 and interferon-α is effective for lung metastasis of renal cell carcinoma: A multicenter open study

被引：27

作者：

Akaza H. ^{[1
]}

Tsukamoto T. ^{[2
]}

Onishi T. ^{[3
]}

Miki T. ^{[4
]}

Kinouchi T. ^{[5
]}

Naito S. ^{[6
]}

机构：

[1] Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba 305-0005

[2] Department of Urology, Sapporo Medical University, Sapporo

[3] Department of Urology, Jikei University, School of Medicine, Tokyo

[4] Department of Urology, Kyoto Prefectural University of Medicine, Kyoto

[5] Department of Urology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka

[6] Kyushu University, School of Medicine, Fukuoka

来源：

International Journal of Clinical Oncology | 2006年 / 11卷 / 6期

关键词：

Combination; IFN-α; Low-dose IL-2; Renal cell carcinoma;

D O I：

10.1007/s10147-006-0596-z

中图分类号：

学科分类号：

摘要：

Background. To confirm the usefulness of a combination therapy of interleukin-2 (IL-2) and interferon-α (IFN-α) against metastatic renal cell carcinoma, the recommended dose of IFN-α to use in combination with low-dose IL-2 was determined (phase 1). Efficacy and safety at this dose was evaluated (phase 2). Methods. In phase 1, the dose of IL-2 was fixed at 0.7 × 106 Japan reference unit (JRU)/person for 5 days a week. The dose of IFN-α was increased from 3 × 106 IU for 3 days a week (level I) to 6 × 106 IU for 3 days a week (level II) and to 6 × 106 IU for 5 days a week (level III). Results. In phase 1, 10 patients were registered, with 9 (3 at each level) able to be evaluated. Because grade 3 and grade 4 neutropenia were observed at level III in 1 patient each, level II was found to be the recommended regimen. The response rate in phase 1 was 44.4% (4/9). In phase 2, 46 patients were registered, with a response rate in 37 patients, classified as per protocol set (PPS), of 21.6% (8/37). Toxicities observed were primarily flu-like symptoms due to cytokines, and gastrointestinal symptoms. Leukocyte abnormalities were observed, but they were milder and tolerable. Conclusion. In the 46 patients evaluated in phase 1 and phase 2, the response rate was 26.1% (12/46), being highest in 38.7% (12/31) of those who were nephrectomized, and with only lung metastases. © 2006 The Japan Society of Clinical Oncology.

引用

页码：434 / 440

页数：6

共 18 条

[11] Fleming T.R., One-sample multiple testing procedure for phase II clinical trials, Biometrics, 38, pp. 143-151, (1982)
[12] Response criteria for urological cancer treatment, Jpn J Urol, 83, pp. 447-472, (1992)
[13] Negrier S., Escudier B., Lasset C., Et al., Recombinant human interleukin-2, recombinant human interferon alpha-2a, or both in metastatic renal-cell carcinoma, N Engl J Med, 338, pp. 1272-1278, (1998)
[14] Fyfe G., Fisher R.I., Rosenberg S.A., Et al., Results of treatment of 255 patients with metastatic renal cell carcinoma who received high dose recombinant interleukin-2 therapy, J Clin Oncol, 13, pp. 688-696, (1995)
[15] Umeda T., Niijima T., Phase II study of alpha interferon on renal cell carcinoma: Summary of three collaborative trials, Cancer, 58, pp. 1231-1235, (1986)
[16] Tourani J.-M., Pfister C., Tubiana N., Et al., Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: Final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design, J Clin Oncol, 21, pp. 3987-3994, (2003)
[17] Dirk S., Heike R., Ralf A., Et al., Phase I clinical and pharmacokinetic study of the novel raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors, J Clin Oncol, 23, pp. 965-972, (2005)
[18] Robert J., Motzer M., Dror M., Et al., Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma, J Clin Oncol, 24, pp. 16-24, (2006)

← 1 2 →